nach oben

The European Journal of Health Economics

Erschienen in:

01.10.2011 | Editorial

Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad

verfasst von: Fernando Antoñanzas, Carmelo Juárez-Castelló, Roberto Rodríguez-Ibeas

Erschienen in: The European Journal of Health Economics | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Excerpt

Patents are defined as a right granted to innovators by governments for the exclusive production and marketing of an innovation for a limited period of time. Patent owners enjoy a legal monopoly. Patents rights have traditionally been considered a good mechanism to provide incentives to innovate as it allows innovators to obtain monopolistic benefits that compensate the R&D expenditures. In the case of the pharmaceutical industry, as imitation of new drugs is relatively easy and it is difficult to keep the ‘first mover’ advantage in the market, it seems that the patent system is the only mechanism to incentive the innovative activity. …

Angell, M.: The truth about the drug companies. How they deceive us and what to do about it. Random House, New York (2004)

Commission on Intellectual Property Rights, Innovation and Public Health: Public health, innovation and intellectual property rights. World Health Organization, Geneva (2006). Available at www.who.int

Correa, C.: Guidelines for the examination of pharmaceutical patents: developing a public health perspective—a working paper. ICTSD, WHO, UNCTAD (2006)

DiMasi, J.A., Grabowski, H.G.: Should the patent system for new medicines be abolished? Clin. Pharmacol. Ther. 82(5), 488–490 (2007)PubMedCrossRef

Danzon, P.M., Towse, A.: Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int. J. Health Care Finance Econ. 3, 183–205 (2003)PubMedCrossRef

Gagnon, M.A., Lexchin, J.: The cost of pushing bills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 5(1), 29–33 (2008)CrossRef

Grabowski, H.G., Wang, Y.R.: The quantity and quality of worldwide new drug introductions, 1982–2003. Health Aff. 25(2), 452–460 (2006)CrossRef

Hong, S.H., Shepherd, M.D., Scoones, D., Wan, T.: Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. J. Manag. Care Pharm. 11(9), 746–754 (2005)PubMed

Kremer, M., Glennerster, R.: Strong medicine: creating incentives for pharmaceutical research on neglected diseases. Princeton University Press, Princeton (2004)

10.

Love, J., Hubbard, T.: The big idea: prizes to stimulate R&D for new medicines (2007). www.keionline.org/misc-docs/bigidea-prizes.pdf

11.

Ridley, D., Grabowski, H., Moe, J.: Developing drugs for developing countries. Health Aff. 25(2), 313–324 (2006)CrossRef

12.

Stiglitz, J.E.: Making globalization work. WW Norton, New York (2006)

13.

WTO: Agreement on trade-related aspects of intellectual property rights (1994). Available at www.wto.org

14.

WTO: Declaration on the TRIPS agreement and public health (WT/MIN(01)/DEC/2) (2001). Available at www.wto.org

Titel: Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad
verfasst von: Fernando Antoñanzas
Carmelo Juárez-Castelló
Roberto Rodríguez-Ibeas
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 5/2011
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-011-0336-9

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor

Comparing top-down and bottom-up costing approaches for economic evaluation within social welfare

Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients

Discrimination in waiting times by insurance type and financial soundness of German acute care hospitals

Contractual conditions, working conditions and their impact on health and well-being

Atrial fibrillation: the cost of illness in Sweden